-transparent.png){kind=logo}
Intracoronary leukotriene D4, 0.1-3.0 micrograms (0.2-6.0 nmol), produced dose-dependent decreases in coronary flow of anesthetized pigs. Pretreatment with intracoronary FPL-55712 (0.1, 0.3 and 1.0 mg) reduced coronary constriction due to 1.0 micrograms leukotriene D4 by up to 77%. FPL-55712 did not produce sustained alterations in coronary flow, left ventricular end-diastolic pressure, systemic arterial pressure, or heart rate. Indomethacin pretreatment (6 mg/kg i.v.) had no effect on leukotriene-induced coronary constriction. Inhibition produced by FPL-55712 may be useful in disease states involving leukotriene-mediated coronary constriction.
Related Publications
L M Boyd, and
D Ezra, and
G Feuerstein, and
R E Goldstein
January 1987,
Advances in prostaglandin, thromboxane, and leukotriene research,
L M Boyd, and
D Ezra, and
G Feuerstein, and
R E Goldstein
April 1990,
Thrombosis research,
L M Boyd, and
D Ezra, and
G Feuerstein, and
R E Goldstein
January 1984,
Prostaglandins,
L M Boyd, and
D Ezra, and
G Feuerstein, and
R E Goldstein
February 1984,
American journal of obstetrics and gynecology,
L M Boyd, and
D Ezra, and
G Feuerstein, and
R E Goldstein
January 1983,
Advances in prostaglandin, thromboxane, and leukotriene research,
L M Boyd, and
D Ezra, and
G Feuerstein, and
R E Goldstein
February 1987,
British journal of pharmacology,
L M Boyd, and
D Ezra, and
G Feuerstein, and
R E Goldstein
November 1985,
The American review of respiratory disease,
L M Boyd, and
D Ezra, and
G Feuerstein, and
R E Goldstein
June 1984,
Prostaglandins, leukotrienes, and medicine,
L M Boyd, and
D Ezra, and
G Feuerstein, and
R E Goldstein
July 1992,
American journal of respiratory cell and molecular biology,
L M Boyd, and
D Ezra, and
G Feuerstein, and
R E Goldstein
January 1986,
Journal of cardiovascular pharmacology,
